Navigating the Regulatory and Valuation Challenges in Health Care Data Transactions
- April 01, 2022
- Rick Schwartz , Kroll, LLC
- Dan Platten , Kroll, LLC
- Richard Church , K&L Gates LLP
- Rebecca Schaefer , K&L Gates LLP
The scale and pace of recent transactions confirm that, more than ever, health care data has substantial value to those seeking to discover, improve, and target therapies. Collaborations are proliferating among health care providers and data aggregators, IT analytics vendors, life sciences firms, genomic testing companies, and additional innovators in the health care space. One such example includes the Truveta and Lexis Nexis partnership announced in January 2022 that will reportedly make available to researchers an unprecedented volume of health care data on a single data platform, encompassing daily clinical data from over 16% of all clinical care in the United States, 40% of all Medicare and Medicaid medical insurance claims, 70% of all commercial medical insurance claims, social determinants of health data on every adult American, and comprehensive mortality data.1 To advance this initiative, Truveta entered a partnership to deploy clinical data on the Azure Cloud platform, and by late 2020, the company was reportedly backed by 17 health care systems.2 Collaborations to make genomic data available to support therapeutic discovery and improvement also continue to be struck by many academic health systems and life sciences companies in the field.3 Notably, Cerner recently augmented its data business with the $375 million acquisition of analytics player Kantar Health4 and the UK Biobank set sights on genomic sequencing of 500,000 participants thanks in part to nearly $250 million in funding from drug manufacturers.5
ARTICLE TAGS
You must be logged in to access this content.